世界の神経学的バイオマーカー市場規模は、2028年までに161億4,000万米ドルに達する見込みです。同市場は、2020年から2028年にかけて12.9%のCAGRで成長すると予想されています。新薬の開発を促進するために、神経学的バイオマーカーの研究開発に対する資金提供が増加していることが、市場の成長を加速させると予想されます。さらに、神経学的バイオマーカー診断のための革新的な新製品の導入が、予測期間中の市場成長を促進すると考えられます。
米国国立神経疾患・脳卒中研究所（National Institute of Neurological Disorders and Stroke）は、バイオマーカーの発見、分析検証、臨床検証に関連する研究を行う研究者に対して、開発補助金や協力協定などの資金を提供しています。このように、研究のさまざまな段階で資金を提供する組織が存在することが、市場の成長を促進すると予想されます。例えば、ノーステキサス大学ヘルスサイエンスセンター（HSC）は、アルツハイマー病と脳の老化における健康格差に関する研究を支援するため、米国国立衛生研究所（NIH）から約4550万米ドルの資金を獲得しました。NIHは、進行中のラテン系高齢者の健康と老化の脳（HABLE：Health and Aging Brain Among Latino Elders）研究のためのバイオマーカー研究に追加の資金を提供しています。
また、製品の発売が増えることも市場の成長を促進すると予想されます。例えば、2021年1月、Abbott社は、UCH-L1およびGFAPバイオマーカーを測定する迅速な携帯型外傷性脳損傷検査のFDA 510K認可を取得しました。この検査の結果は15分以内に得られ、臨床医がCTスキャンを行う必要性を評価するのに役立ちます。この検査の迅速な結果は、医師が治療計画を立て、時間通りに治療を行うのに役立ちます。
2018年8月、Olink Proteomics AB社は、高品質なタンパク質アッセイのポートフォリオを拡大するために、新しいバイオマーカーパネルOlink NEURO EXPLORATORYを発表しました。本製品には、外傷性脳損傷や変性神経疾患の重要なバイオマーカーであるニューロフィラメントライトポリペプチドの高性能アッセイが含まれています。
しかし、バイオマーカーに対する保険償還が行われていないことが、市場の成長を妨げています。現在、認知症の症状に対するバイオマーカー検査は、特定の制限された形でのみメディケアやその他の健康保険プログラムでカバーされており、その使用は個人の症状や特定の要件に基づいて正当化されなければなりません。
アルツハイマー病の償還も、Blue Cross社やBlue Shield Association社などのほとんどの保険会社からは提供されていません。インドや中国などの発展途上国では、保険の普及率が低く、バイオマーカー検査に関する認知度も低いため、神経学的バイオマーカー検査の保険適用範囲はさらに狭くなっています。
目次
Table of Contents
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Neurological Biomarkers Market Variables, Trends, and Scope
3.1 Neurological Biomarkers Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Pipeline Analysis
3.3.1 Alzheimer’s Disease
3.3.2 Parkinson’s Disease
3.3.3 Multiple Sclerosis
3.3.4 Autism Spectrum Disorder
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Increasing Prevalence Of Neurological Diseases
3.4.1.2 Technological Advancements
3.4.1.3 Increased Funding For R&D In Biomarkers
3.4.2 Market Restraint Analysis
3.4.2.1 Lack of consumer awareness
3.4.2.2 Reimbursement policies
3.5 Neurological Biomarkers: Market Analysis Tools
3.5.1 Industry Analysis - Porter’s
3.5.2 Pestle Analysis
Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2017 - 2028 (USD Million)
4.1 Definition and Scope
4.2 Type Market Share Analysis, 2020 & 2028
4.3 Segment Dashboard
4.4 Global Neurological Biomarkers Market, by Type, 2017 to 2028
4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
4.5.1 Genomic
4.5.1.1 Genomic Neurological Biomarkers Market, 2017 - 2028 (USD Million)
4.5.2 Proteomic
4.5.2.1 Proteomic Neurological Biomarkers Market, 2017 - 2028 (USD Million)
4.5.3 Metabolomic
4.5.3.1 Metabolomic Neurological Biomarkers Market, 2017 - 2028 (USD Million)
4.5.4 Imaging
4.5.4.1 Imaging Market Estimates And Forecast, 2016 - 2028 (USD Million)
4.5.5 Others
4.5.5.1 Others market, 2017 - 2028 (USD Million)
Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2017 - 2028 (USD Million)
5.1 Definition and Scope
5.2 Application Market Share Analysis, 2020 & 2028
5.3 Segment Dashboard
5.4 Global Neurological Biomarkers Market, by Application, 2017 to 2028
5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
5.5.1 Alzheimer’s Disease
5.5.1.1 Alzheimer’s Disease Market, 2017 - 2028 (USD Million)
5.5.2 Parkinson’s Disease
5.5.2.1 Parkinson’s Disease Market, 2017 - 2028 (USD Million)
5.5.3 Multiple Sclerosis
5.5.3.1 Multiple Sclerosis Market, 2017 - 2028 (USD Million)
5.5.4 Autism Spectrum Disorder
5.5.4.1 Autism Spectrum Disorder Market, 2017 - 2028 (USD Million)
5.5.5 Others
5.5.5.1 Others market, 2017 - 2028 (USD Million)
Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End Use, 2017 - 2028 (USD Million)
6.1 Definition and Scope
6.2 End-use Market Share Analysis, 2020 & 2028
6.3 Segment Dashboard
6.4 Global Neurological Biomarkers Market, by End Use, 2017 to 2028
6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
6.5.1 Hospital & Hospital Laboratories
6.5.1.1 Hospitals & Hospital Laboratories Market, 2017 - 2028 (USD Million)
6.5.2 Independent Clinical Diagnostic Centers
6.5.2.1 Independent Clinical Diagnostic Centers Market, 2017 - 2028 (USD Million)
6.5.3 Research Organizations And Others
6.5.3.1 Research Organizations and Others market, 2017 - 2028 (USD Million)
Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2017 - 2028 (USD Million)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2020 & 2028
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Regional Market Share and Leading Players, 2020
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 Middle East And Africa
7.6 SWOT Analysis
7.6.1 NORTH AMERICA
7.6.2 Europe
7.6.3 Asia Pacific
7.6.4 Latin America
7.6.5 Middle East And Africa
7.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2020 to 2028
7.7.1 North America
7.7.1.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
7.7.1.2 The U.S.
7.7.1.2.1 The U.S. Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.1.3 Canada
7.7.1.3.1 Canada Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.2 Europe
7.7.2.1 Europe Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.2.2 The U.K.
7.7.2.2.1 The U.K. Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.2.3 Germany
7.7.2.3.1 Germany Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.2.4 Spain
7.7.2.4.1 Spain Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.2.5 France
7.7.2.5.1 France Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.2.6 Italy
7.7.2.6.1 Italy Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.3 Asia Pacific
7.7.3.1 Asia Pacific Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.3.2 Japan
7.7.3.2.1 Japan Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.3.3 China
7.7.3.3.1 China Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.3.4 India
7.7.3.4.1 India Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.3.5 South Korea
7.7.3.5.1 South Korea Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.3.6 Australia
7.7.3.6.1 Australia Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.4 Latin America
7.7.4.1 Latin America Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.4.2 Brazil
7.7.4.2.1 Brazil Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.4.3 Mexico
7.7.4.3.1 Mexico Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.4.4 Argentina
7.7.4.4.1 Argentina Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.5 MEA
7.7.5.1 MEA Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.5.2 South Africa
7.7.5.2.1 South Africa Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.5.3 Saudi Arabia
7.7.5.3.1 Saudi Arabia Neurological Biomarkers market, 2017 - 2028 (USD Million)
7.7.5.4 UAE
7.7.5.4.1 UAE Neurological Biomarkers market, 2017 - 2028 (USD Million)
Chapter 8 Neurological Biomarkers Market: Competitive Analysis
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 New Product Launches
8.1.2 Mergers And Acquisitions
8.1.3 Partnerships And Licensing Agreements
8.1.4 Conferences And Campaigns
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.2.3 Heat Map Analysis
8.3 Vendor Landscape
8.3.1 List Of Key Distributors And Channel Partners
8.3.2 Key Customers
8.4 Public Companies
8.4.1 Company Market Position Analysis
8.4.2 Company Market Position Analysis
8.4.3 Competitive Dashboard Analysis
8.4.3.1 Market Differentiators
8.5 Private Companies
8.5.1 List Of Key Emerging Companies
8.6 Company Profiles
8.6.1 ABBOTT
8.6.1.1 Company overview
8.6.1.2 Financial performance
8.6.1.3 Product benchmarking
8.6.1.4 Strategic initiatives
8.6.2 JOHNSON & JOHNSON SERVICES, INC.
8.6.2.1 Company overview
8.6.2.2 Financial performance
8.6.2.3 Product benchmarking
8.6.2.4 Strategic initiatives
8.6.3 BIO-RAD LABORATORIES, INC.
8.6.3.1 Company overview
8.6.3.2 Financial performance
8.6.3.3 Product benchmarking
8.6.3.4 Strategic initiatives
8.6.4 ALSERES PHARMACEUTICALS, INC.
8.6.4.1 Company overview
8.6.4.2 Product benchmarking
*Pipeline candidate
8.6.5 BANYAN BIOMARKERS, INC.
8.6.5.1 Company overview
8.6.5.2 Product benchmarking
8.6.5.3 Strategic initiatives
8.6.6 MYRIAD RBM (MYRIAD GENETICS, INC.)
8.6.6.1 Company overview
8.6.6.2 Financial performance
8.6.6.3 Product benchmarking
8.6.6.4 Strategic initiatives
8.6.7 THERMO FISHER SCIENTIFIC, INC.
8.6.7.1 Company overview
8.6.7.2 Financial performance
8.6.7.3 Product benchmarking
8.6.7.4 Strategic initiatives
8.6.8 DIAGENIC ASA
8.6.8.1 Company overview
8.6.8.2 Product benchmarking
8.6.9 MERCK & CO., INC.
8.6.9.1 Company overview
8.6.9.2 Financial performance
8.6.9.3 Product benchmarking
8.6.9.4 Strategic initiatives
8.6.10 QUANTERIX
8.6.10.1 Company overview
8.6.10.2 Product benchmarking
8.6.10.3 Strategic initiatives
List of Tables
TABLE 1 List of Abbreviation
TABLE 2 North America neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 3 North America neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 4 North America neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 5 The U.S. neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 6 The U.S. neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 7 The U.S. neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 8 Canada neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 9 Canada neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 10 Canada neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 11 Europe neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 12 Europe neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 13 Europe neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 14 The U.K. neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 15 The U.K. neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 16 The U.K. neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 17 Germany neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 18 Germany neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 19 Germany neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 20 France neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 21 France neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 22 France neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 23 Italy neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 24 Italy neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 25 Italy neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 26 Spain neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 27 Spain neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 28 Spain neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 29 Asia Pacific neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 30 Asia Pacific neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 31 Asia Pacific neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 32 Japan neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 33 Japan neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 34 Japan neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 35 China neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 36 China neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 37 China neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 38 India neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 39 India neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 40 India neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 41 South Korea neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 42 South Korea neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 43 South Korea neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 44 Australia neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 45 Australia neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 46 Australia neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 47 Latin America neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 48 Latin America neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 49 Latin America neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 50 Brazil neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 51 Brazil neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 52 Brazil neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 53 Mexico neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 54 Mexico neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 55 Mexico neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 56 Argentina neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 57 Argentina neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 58 Argentina neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 59 MEA neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 60 MEA neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 61 MEA neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 62 South Africa neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 63 South Africa neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 64 South Africa neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 65 Saudi Arabia neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 66 Saudi Arabia neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 67 Saudi Arabia neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
TABLE 68 UAE neurological biomarkers market, by application, 2017 - 2028 (USD Million)
TABLE 69 UAE neurological biomarkers market, by type, 2017 - 2028 (USD Million)
TABLE 70 UAE neurological biomarkers market, by end-use, 2017 - 2028 (USD Million)
List of Figures
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global neurological biomarkers market- Key market driver analysis
FIG. 7 Global neurological biomarkers market - Key market restraint analysis
FIG. 8 Penetration & growth prospect mapping
FIG. 9 Global neurological biomarkers market - Porter’s analysis
FIG. 10 Global neurological biomarkers market - PESTEL analysis
FIG. 11 Global neurological biomarkers market application outlook key takeaways
FIG. 12 Global neurological biomarkers market: Application movement analysis
FIG. 13 Alzheimer’s disease market estimates, 2017 - 2028 (USD Million)
FIG. 14 Parkinson’s disease market estimates, 2017 - 2028 (USD Million)
FIG. 15 Multiple sclerosis market estimates, 2017 - 2028 (USD Million)
FIG. 16 Autism spectrum disorders market estimates, 2017 - 2028 (USD Million)
FIG. 17 Others market estimates, 2017 - 2028 (USD Million)
FIG. 18 Global neurological biomarkers market type outlook key takeaways
FIG. 19 Global neurological biomarkers market: Type movement analysis
FIG. 20 Genomic market estimates, 2017 - 2028 (USD Million)
FIG. 21 Proteomic market estimates, 2017 - 2028 (USD Million)
FIG. 22 Metabolomic market estimates, 2017 - 2028 (USD Million)
FIG. 23 Imaging market estimates, 2017 - 2028 (USD Million)
FIG. 24 Others market estimates, 2017 - 2028 (USD Million)
FIG. 25 Global neurological biomarkers market end-use outlook key takeaways
FIG. 26 Global neurological biomarkers market: End-use movement analysis
FIG. 27 Hospital laboratories market estimates, 2017 - 2028 (USD Million)
FIG. 28 Independent clinical diagnostic centers market estimates, 2017 - 2028 (USD Million)
FIG. 29 Research organizations market estimates, 2017 - 2028 (USD Million)
FIG. 30 Others market estimates, 2017 - 2028 (USD Million)
FIG. 31 Regional marketplace: Key takeaways
FIG. 32 Global neurological biomarkers market: Regional movement analysis
FIG. 33 North America neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 34 The U.S. neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 35 Canada neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 36 Europe neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 37 The U.K. neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 38 Germany neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 39 France neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 40 Spain neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 41 Italy neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 42 Asia Pacific neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 43 Japan neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 44 China neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 45 India neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 46 South Korea neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 47 Australia neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 48 Latin America neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 49 Brazil neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 50 Mexico neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 51 Argentina neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 52 MEA neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 53 South Africa neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 54 Saudi Arabia neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 55 UAE neurological biomarkers market, 2017 - 2028 (USD Million)
FIG. 56 Strategy framework
